MAY 14, 2010; Direct Strategy makes investment in Provista Life Sciences

MAY 14, 2010: Provista is the developer of the Biomarker Translation (BT) and LymPro Test. The BT Test, is a blood test that detects and measures the levels of key biomarkers that are associated with breast cancer. A biomarker is a protein found in the blood whose presence can indicate the existence of disease. The BT Test has successfully demonstrated an accuracy of greater than 80 percent in studies involving breast cancer-positive and non-breast cancer subjects, the latter group. "Provista is a classic example of intellectual property which is ahead of market acceptance", said Antonio De La Rosa, Managing Director of Direct Strategy.

Direct Strategy  |  8777 North Gainey Center  |  Suite 136 Scottsdale, AZ 85258  |  Direct Strategy 2008 All Rights Reserved.